Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cogstate Ltd ( (AU:CGS) ) has shared an update.
Cogstate Ltd announced that its CEO, Brad O’Connor, sold 338,429 shares to fund the exercise of 399,500 employee share options and to manage related debts and tax obligations. Following these transactions, Mr. O’Connor’s shareholding increased to 6,400,000 ordinary shares. This strategic move reflects the CEO’s commitment to maintaining a significant stake in the company while managing financial obligations, potentially impacting stakeholder confidence and market perception.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that focuses on optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners with electronic clinical outcome assessment solutions. Cogstate has been supporting biopharmaceutical companies, academic institutions, and healthcare providers for over 20 years, offering digital measures of cognition for primary care physicians and consumers.
Average Trading Volume: 183,737
Technical Sentiment Signal: Buy
Current Market Cap: A$419.5M
See more insights into CGS stock on TipRanks’ Stock Analysis page.